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European Respiratory Journal
Dear Prof. M. Kolb, 
 
We thank the Journal and Reviewers for their positive feedback. The minor 
modifications were integrated into our manuscript as listed below.  
 
Yours sincerely, 
 
Prof. Heinzer for the coauthors 
 
Reviewer: 1  
The authors have done an excellent job addressing my concerns. I only found 
a few minor errors that the authors should correct. 
 
1) In the abstract, please change "AHI10<10/h" to AHI<10/h. 
The change was done. 
 
2) In the Results, the description of Figure 2 is a bit confusing. The authors 
provide the p-values and odds ratio for just the moderate-to-severe REM SDB (REM 
AHI > 20). However, the figure also has a p for trend. In other words, the highest 
category of REM AHI is associated with diabetes and a trend for depression, but the 
p-value for trend (which compares all the four groups) is not significant for diabetes 
and depression. Perhaps what the authors can do is to rephrase the paragraph so it 
is more clear. For example, they could state the following: "Although the p-value for 
trend was not significant for diabetes or depression, the subgroup with the highest 
severity of REM SDB (i.e. REM AHI > 20/h) had significantly higher odds of diabetes 
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(OR=3.12 [1.35-7.20], p=0.008) and a trend towards higher odds of depression 
(OR=2.14 [0.99-4.64], p=0.054) when compared to the group with no REM SDB (i.e. 
REM AHI < 5/h)." This way, the readers will not be confused by the differing p values 
in the text and in the figure. 
We thank the Reviewer for the suggestion. The p-value for trend was 
significant for diabetes (p trend=0.039). Thus, we have incorporated the suggestion 
with some modification as follows: “Increasing REM-AHI severity was significantly 
associated with metabolic syndrome and diabetes, while hypertension and 
depression showed no association with REM-SDB. Although the p-value for trend 
was not significant for depression, the subgroup with the highest severity of REM-
SDB (i.e. REM-AHI>20/h) had a trend towards higher odds of depression (OR=2.14 
[0.99-4.64], p=0.054) when compared to the group with no REM-SDB (i.e. REM-
AHI<5/h).” 
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“Take Home” Message: REM sleep-disordered breathing is highly prevalent and is 
associated with metabolic syndrome and diabetes. 
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 ABSTRACT 
Study Objectives: This study determined the prevalence of rapid eye movement-related 
sleep-disordered breathing (REM-SDB) in the general population, and investigated the 
associations of REM-SDB with hypertension, metabolic syndrome, diabetes and depression. 
Methods: 2074 home polysomnography (PSG) recordings from the population-based 
HypnoLaus Sleep Cohort (48.3% men, 57±11 years old) were analysed. The apnoea–
hypopnoea index was measured during REM (REM-AHI) and non-REM (NREM-AHI) sleep. 
Regression models were used to explore the association between REM-SDB and 
hypertension, diabetes, metabolic syndrome and depression in the entire cohort and in 
subgroups with NREM-AHI<10/h and total AHI<10/h. 
Results: Prevalence of REM-AHI≥20/h was 40.8% in the entire cohort. An association 
between increasing REM-AHI and metabolic syndrome was found in the entire cohort and 
in both subgroups (p-trend=0.014, <0.0001 and 0.015, respectively). An association was 
also found between REM-AHI≥20/h and diabetes in both NREM-AHI<10/h (OR=3.12 [1.35-
7.20]) and AHI<10/h (OR=2.92 [1.12-7.63]) subgroups. Systolic and diastolic blood 
pressure were positively associated with REM-AHI≥20/h. 
Conclusions: REM-SDB is highly prevalent in our middle-to-older age sample and is 
independently associated with metabolic syndrome and diabetes. These findings suggest 
that an increase in REM-AHI could be clinically relevant. 
 
Keywords: REM, sleep apnea, sleep-disordered breathing, metabolic syndrome, diabetes, 
depression, hypertension. 
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 Introduction 
Sleep-disordered breathing (SDB) is highly prevalent in the general population [1], 
causing intermittent hypoxaemia, microarousals, sleep fragmentation, and acute changes in 
blood pressure and heart rate. SDB during rapid eye movement sleep (REM-SDB) is 
estimated to occur in 10–36% of patients with SDB [2], but its prevalence in the general 
population is not yet known.  
REM-SDB is more common in patients with mild and moderate SDB [3] and has a 
higher prevalence in younger women than in men [4]. Data about sleepiness and REM-SDB 
are conflicting, but studies found no association between REM-SDB and daytime 
sleepiness or reduced quality of life [5-8]. 
Nocturnal respiratory events are usually more frequent and of longer duration in 
REM compared with NREM sleep, probably due to greater pharyngeal muscle relaxation [9-
11] and a reduction in the hypoxic and hypercapnic ventilatory response throughout REM 
sleep [12, 13]. 
Along with intermittent hypoxia, elevated sympathetic activity is thought to be the 
most important mechanism underlying the increased cardiovascular risk associated with 
SDB [14]. Compared with NREM sleep, REM sleep is associated with higher sympathetic 
activity and cardiovascular instability [15-17]. Recent studies have shown an association 
between REM-SDB and non-dipping nocturnal blood pressure and hypertension [18-20], 
and REM-SDB has further been reported to have an adverse effect on long-term glycaemic 
control and insulin resistance [21, 22]. However, the specific impact of REM-SDB on 
cardiovascular risk factors and psychiatric comorbidities is not yet known. 
This study evaluated the prevalence of REM-SDB in the general population and 
investigated the associations between REM-SDB and cardiovascular, metabolic and 
psychiatric comorbidities. 
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 Methods 
Population sample 
The HypnoLaus Sleep Cohort study has been described previously [1]. It included a 
random subset of the population-based CoLaus/PsyCoLaus cohort [23, 24] who underwent 
full polysomnography (PSG) at home and answered questionnaires about their sleep 
complaints, including the Epworth Sleepiness Scale (ESS) [25]. The ethics committee of the 
University of Lausanne approved the CoLaus/PsyCoLaus cohort study and the HypnoLaus 
Sleep Cohort study. Written informed consent was obtained from all participants. 
 
Sleep data analysis 
PSG was performed by certified technicians who equipped participants with a 
polysomnographic recorder (Titanium, Embla Flaga, Reykjavik, Iceland) in accordance with 
2007 American Academy of Sleep Medicine (AASM) recommended setup specifications 
[26] at the Center for Investigation and Research in Sleep (CIRS) at the University Hospital 
of Lausanne. All PSGs took place in the patients’ home environment. Sleep stages were 
scored in 30-second epochs according to the 2007 AASM criteria [27]. Apnoeas, 
hypopnoeas, and respiratory effort-related arousals were scored according to the 2012 
AASM criteria [28]. 
The average number of apnoeas-hypopnoeas per hour of sleep (apnoea–hypopnoea 
index [AHI]) was calculated for the whole night, and for REM and NREM sleep separately. 
Percentage of total sleep time (TST) with oxygen saturation below 90% (T90) and the 
number of ≥3% oxygen desaturations per hour (oxygen desaturation index [ODI]) were 
assessed. 
Quality control for concordance between the two PSG scorers was implemented 
periodically to ensure that both achieved at least 90% agreement for sleep stages and 
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 respiratory events, and 85% agreement for arousals. An expert sleep clinician reviewed 
every recording and a second sleep expert performed quality checks. We asked individuals 
who were currently receiving treatment for SDB (n=38) to discontinue their treatment 1 
week before the sleep recording. 
 
Outcome variables 
Body weight and height were measured with participants standing without shoes in 
light indoor clothes. Body weight was measured in kilograms to the nearest 100g using a 
Seca® scale, which was calibrated regularly. Height was measured to the nearest 5 mm 
using a Seca® height gauge. Body mass index (BMI) was calculated as weight (kg)/height 
(m2). 
Waist was measured with a non-stretchable tape over the unclothed abdomen at the 
narrowest point between the lowest rib and the iliac crest. Hip was measured at the largest 
part of the hips. For waist and hip, two measures were made and the mean (expressed in 
centimeters) was used to assess waist-to-hip ratio (WHR). Neck circumpherence was 
measured at the middle of the neck between the mid-cervical spine and superior line of the 
cricothyroid membrane. 
Blood pressure was measured thrice on the left arm in the morning and the average 
of the last two readings was considered. Arterial hypertension was defined as systolic blood 
pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or current use of 
antihypertensive drugs. Diabetes was defined as fasting blood glucose ≥7 mmol/L or 
current antidiabetic drug treatment. Metabolic syndrome was defined according to the Adult 
Treatment Panel III (ATP-III) report [29]. Smoking status, alcohol consumption and the 
number of alcoholic drinks taken before the PSG recording and weekly were self-reported. 
The semi-structured Diagnostic Interview for Genetic Studies (DIGS) was used to diagnose 
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 current major depressive disorder, which was defined according to criteria of the Diagnostic 
and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) [30].  Interviewers were 
required to be masters-level psychologists, and were trained over a two-month period. 
During data collection, each interview was reviewed by an experienced senior clinical 
psychologist. The DIGS interview systematically assesses the last and the most severe 
depressive episodes.  
 
Statistical analysis 
All statistical analyses were performed with IBM SPSS version 21.0 (IBM 
Corporation, Armonk, NY, USA). Bivariate analyses were performed using Chi-squared test 
for categorical variables and Kruskal-Wallis for continuous variables. Pairwise comparisons 
were performed using Mann-Whitney test with Bonferroni’s correction for p-value. Logistic 
regression models were used to estimate the association between REM-SDB and the 
presence of hypertension, diabetes, metabolic syndrome and depression. REM-AHI was 
classified into four severity categories (REM-AHI <5/h [reference group]; 5–9.9/h; 10–
19.9/h; and ≥20/h) for the primary analysis (according to previous results of the HypnoLaus 
cohort) and used as continuous variable for a sensitivity analysis. A linear regression model 
was also used to assess the association between REM-AHI (as continuous and dummy 
variable) and diastolic and systolic blood pressure. 
Analyses were performed on the entire cohort and in two subgroups: one restricted 
to subjects with a total AHI<10/h (absent or mild SDB), and another in those with NREM-
AHI<10/h (exclusive REM-SDB). For hypertension, diabetes and metabolic syndrome, the 
models were adjusted for age, sex, BMI, WHR, TST, logarithme of NREM-AHI (log-NREM-
AHI), smoking and alcohol consumption. An additional adjustment for antihypertensive 
treatment was added when SBP and DBP were used as outcome variables in the linear 
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 regression models. For depression, the model was adjusted for age, sex, and consumption 
of benzodiazepines and antidepressants. Results were expressed as odds ratio (OR) and 
95% confidence interval. Statistical significance was condidered for a two-sided test p<0.05 
and p<0.008 for multiple comparisons in univariate analysis. 
Results 
Study population 
Of the 2168 subjects (48.3% men, 59±11 y.o, range 40-85, body mass index 25.6 ± 
4.1 kg/m2) who underwent complete PSG at home, 60 (3%) had technical problems, 54 
underwent a second recording and six subjects refused resulting in 2162 valid PSG 
recordings. Of these, 41 with less than four hours of TST were excluded to avoid the risk of 
unbalanced representation of different sleep stages. We also excluded 47 patients with <30 
minutes of REM sleep to allow a proper assessment of REM sleep [18, 19]. Therefore, 
2074 PSG recordings were included in the analysis. Clinical and polysomnographic 
characteristics of the total sample are shown in Table 1. 
 
REM-SDB in the entire cohort 
The overall prevalence of moderate-to-severe REM-SDB (REM-AHI ≥20/h) was 
40.8% in HypnoLaus middle-to-older age general population sample. As REM-AHI 
increased, there was a corresponding increase in mean age, BMI, WHR and neck 
circumference as well as in the prevalence of hypertension, diabetes and metabolic 
syndrome (Table 1). Patients in the higher REM-AHI severity categories had lower TST, 
and lower proportions of slow wave sleep (SWS) and REM sleep. They also had higher ODI 
and arousal index and spent more time with oxygen saturation <90% (T90), but there was 
no difference in the ESS score between the REM-SDB severity categories. 
Figure 1 shows the results for the association of REM-SDB with metabolic syndrome, 
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 diabetes, hypertension and depression. REM-AHI categories of 5-9.9/h (OR=1.78 [1.13-
2.81], p=0.013), 10-19.9/h (OR=1.69 [1.12-2.57], p=0.013), and ≥20/h (OR=1.94 [1.29-
2.92], p=0.001) were independently associated with metabolic syndrome, but not diabetes 
and depression. Although we found no association between hypertension and REM-SDB, 
there was a significant association of REM-AHI≥20/h with both systolic and diastolic blood 
pressure (Table 4). 
 
NREM-AHI <10/h (exclusive REM-SDB) 
A subgroup of 1241 subjects (59.8%) with NREM-AHI<10/h was analysed to better 
define the specific influence of REM-SDB (Table 2). In this subgroup, the prevalence of 
moderate-to-severe REM-SDB (REM-AHI≥20/h) was 21.2% (n=263). As in the overall 
analysis, patients in the highest REM-AHI severity categories were older and had higher 
BMI, WHR and neck circumference, and a higher prevalence of hypertension, diabetes and 
metabolic syndrome. 
TST and REM sleep time were reduced only in the REM-AHI≥20/h group, while 
arousal index, ODI and T90 was increased in all REM-SDB subgroups. No significant 
differences were found in SWS time and ESS score among the REM-SDB severity 
categories. 
The same multivariate models were applied to this subgroup (Figure 2). Increasing 
REM-AHI severity was significantly associated with metabolic syndrome and diabetes, 
while hypertension and depression showed no association with REM-SDB. Although the p-
value for trend was not significant for depression, the subgroup with the highest severity of 
REM-SDB (i.e. REM-AHI>20/h) had a trend towards higher odds of depression (OR=2.14 
[0.99-4.64], p=0.054) when compared to the group with no REM-SDB (i.e. REM-AHI<5/h). 
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 Total AHI<10/h (absent or mild SDB) 
 A second subgroup of 1047 subjects (50.5%) with total AHI<10/h was analysed to 
evaluate the prevalence and significance of REM-SDB in subjects with absent or mild SDB 
(Table 3). In this subgroup the prevalence of moderate-to-severe REM-SDB (REM-
AHI≥20/h) was 9.1% (n=95). As observed in the exclusive REM-SDB subgroup and the 
overall population, increasing REM-AHI severity was associated with higher mean age, 
BMI, WHR, neck circumference, and a higher prevalence of metabolic syndrome, diabetes 
and hypertension in univariate analysis. 
Only the REM-AHI≥20/h group presented lower TST and REM sleep time compared 
to the other groups, while all REM-SDB subgroups presented increased arousal index 
compared to REM-AHI<5/h. Subjects with higher REM-AHI showed increased ODI and 
T90. No significant differences were found in SWS time and ESS score across the REM-
AHI categories. 
Figure 3 shows the results of the logistic regression models applied to this subgroup. 
There was a significant association of moderate-to-severe REM-SDB with both metabolic 
syndrome and diabetes, but not hypertension or depression. 
We performed the same analysis using REM-AHI as continuous variable instead of 
REM-AHI categories with the same covariables previously described. Using these models, 
we also found significant associations between REM-AHI and metabolic syndrome in the 
entire cohort and the two subgroups, and with diabetes in both NREM-AHI<10/h and 
AHI<10/h subgroups (Table S1). However, no association was significant for hypertension 
and depression. 
 
Discussion 
To our knowledge, this is the first study demonstrating an independent association of 
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 REM-SDB with metabolic syndrome and diabetes in the general population. We also 
showed in this analysis that the prevalence of moderate-to-severe REM-SDB (REM-
AHI≥20/h) in this middle to older age general population sample was 40.6%, and that nearly 
10% of patients with a global AHI of <10/h have moderate-to-severe REM-SDB. These 
findings may have important implications for routine clinical practice in sleep medicine 
because they suggest that REM-AHI may need to be considered independently from global 
AHI when interpreting PSG results in patients at risk for metabolic dysfunction.  
 
REM-SDB and metabolic syndrome 
Several studies have shown a relationship between SDB and metabolic syndrome [1, 
31, 32], but none of them assessed the relationship with REM-SDB. In the present study, 
there was a clear and independent association between increasing REM-AHI severity and 
the presence of metabolic syndrome. This association was found in the whole sample as 
well as in subjects with absent or mild SDB (AHI<10/h) and in those with exclusive REM-
SDB (NREM-AHI<10/h). This suggests that apnoeas and hypopnoeas occurring during 
REM sleep may have a specific association with the metabolic syndrome. 
 
REM-SDB and diabetes 
Previous studies showed an association between REM-AHI severity and increasing 
levels of glycosylated haemoglobin (HbA1c) in patients with type 2 diabetes (T2DM) and 
with insulin resistance [21, 22]. In the present study we found a significant and independent 
association between diabetes and REM-SDB in both subgroups with NREM-AHI<10/h and 
AHI<10/h. Recently, Mokhlesi et al described an improvement in glycaemic control in 
patients with T2DM and SDB after one week of 8-hour nightly continuous positive airway 
pressure (CPAP) [33]. However, another study, in which CPAP was used for a mean of 4.3 
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 hours per night, showed no significant improvement in glycaemic control in patients with 
T2DM and SDB [34]. The better results obtained by Mokhlesi and colleagues could be 
related to the longer duration of CPAP usage resulting in better control of REM-SDB, 
because REM sleep mainly occurs toward the end of the night. We can thus speculate that 
the negative results reported by previous studies with shorter CPAP usage (usually limited 
to the first hours of the night) may be due to insufficient treatment of REM-SDB in the 
second part of the night. The importance of longer nightly CPAP use was also recently 
suggested by the results of the SAVE study where a significant decrease in 
cerebrovascular events was present only in patients with moderate-to-severe sleep apnoea 
and coronary or cerebrovascular disease who used CPAP for more than four hours per 
night [34, 35]. It is howerver unclear why this association was found mainly in the group 
with NREM-AHI<10 in our study. 
Different hypotheses can be proposed regarding the underlying mechanisms of the 
associations between REM-SDB and metablic syndrome or diabetes. First, it is well 
established that respiratory events occurring during REM sleep have a longer duration and 
generate greater oxygen desaturations compared to NREM events [9-11]. This may trigger 
increased oxidative stress compared with other respiratory events, which could promote 
metabolic syndrome and diabetes. Acute intermittent hypoxia was also shown to acutely 
increase insulin resistance in healthy volunteers [36]. In addition, compared to NREM sleep, 
sympathetic activity is greater during REM sleep and most endocrine organs implicated in 
glucose metabolism are sensitive to changes in sympathovagal balance [37-39]. 
Furthermore, SDB in REM reversed the physiological nocturnal decline of interstitial 
glucose concentration (IGC), while NREM-SDB had no effect on IGC [40]. Lastly, nocturnal 
hyperglycaemia associated with SDB in patients with diabetes was shown to be specifically 
accentuated during REM sleep [41]. 
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REM-SDB and hypertension 
We previously reported a significant association between SDB severity and 
hypertension in the population-based HypnoLaus sleep cohort [1]. Considering that two 
studies have shown a specific association between REM-SDB and increased incident 
hypertension [18, 19], we tested this association in our sample using a cross-sectional 
analysis. Surprisingly, there was no significant association between REM-SDB and 
hypertension in the whole sample nor in the subgroups with REM-AHI<10/h or global 
AHI<10/h. The reason for these differences between our and previous studies is unclear. In 
the Wisconsin cohort, the scoring of hypopnoeas required a 4% oxygen desaturation, which 
may have selected more severe respiratory events [42]. However, the MAILES study, which 
also found a significant association between REM-SDB and hypertension, used the 
currently recommended 3% criteria for scoring hypopnoeas [19]. Another difference is that 
the MAILES study included only males, whereas we included both genders in our analysis. 
However, this is unlikely to explain the lack of association we found because our models 
were also negative when we restricted the analysis to men (data not shown). The analysis 
by Mokhlesi and colleagues on the Wisconsin cohort used 24-hour blood pressure 
monitoring while we used three measurements in the morning. Although this is a potential 
source of difference between the two studies, the MAILES study used the same technique 
as in the present study and found a significant association between REM-SDB and 
hypertension. When using blood pressure as a continuous dependent variable, there was 
however a significant positive association between moderate-to-severe REM-AHI and both 
systolic and diastolic blood pressure. These findings appear to suggest a possible positive 
association between REM-SDB and blood pressure. 
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 REM-SDB and depression 
We did not find a significant association between depression and REM-SDB, besides 
a trend in the NREM-AHI<10/h subgroup. Our group and others have previously shown that 
patients with SDB are at higher risk of depressive disorders [1, 43-45] and have a greater 
prevalence of other psychiatric comorbidities [46-48]. However, the mechanisms underlying 
the possible association between REM-SDB and depression are not clear. Oxygen 
desaturation and hypoxia during sleep have been proposed as potential mechanisms for 
this association because interventional studies using oxygen or CPAP therapies [49, 50] 
found that reversing hypoxaemia in SDB improved mood disorders. Moreover, due to its 
likely role in emotion processing, REM sleep fragmentation could have a negative impact 
on mood [51]. However, we did not find an independent association of depression with ODI, 
T90, and arousal index (data not shown).  
 
Strengths and limitations 
The main strength of this study is the inclusion of a large sample representative of 
the general population and the extensive phenotyping of participants, which allowed the 
creation of models controlling for the main confounding factors for each analysed outcome. 
However, our study also has limitations that need to be aknowledged. First, the cross-
sectional design does not allow any causality relationships to be determined. Second, the 
study population was aged between 40 and 85 years and essentially of white European 
origin with a low prevalence of obesity. Thus, generalizability of our findings to younger, 
more obese populations of different ethnicity is not possible. Lastly, we did not use the 
dichotomized definition of REM-SDB proposed by others [2-4]. However, we believe that 
the use of REM-AHI severity categories allows more precise analysis than a dichotomous 
classification. 
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 In conclusion, our findings show that moderate-to-severe REM-SDB is highly 
prevalent in the general population, even in individuals classified as having absent or mild 
SDB, and that REM-SDB is independently associated with important cardiovascular risk 
factors such as metabolic syndrome and diabetes. Because CPAP use is often limited to 
the first part of the night (leaving the most REM-SDB untreated), our results strenghten the 
concept that patients should be encouraged to use CPAP for the whole night to obtain 
maximum benefit. 
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 Table 1. Subject's characteristics in the entire cohort based on REM-AHI severity. 
REM-AHI severity categories in the entire cohort  
  All <5/h 5-9.9/h 10-19.9/h ≥20/h p-value 
Number of subjects, % (n) 100 (2074) 22.0 (456) 16.0 (331) 21.3 (441) 40.8 (846)   
Female, % (n) 52.0 (1079) 69.7 (318)* 57.1 (189)* 49.9 (220) 41.6 (352) <0.0001 
Age, years, Median (IQR) 56.3 (48.5 - 66.2) 51.3 (45.6 - 59.6) 54.1 (47.0 - 63.1)* 55.9 (48.9 - 65.7)* 60.6 (52.5 - 68.4)*
+#
 <0.0001 
BMI, kg/m
2
, Median (IQR) 25.7 (23.2 - 28.5) 23.7 (21.5 - 26.3) 24.2 (22.1 - 26.5) 25.6 (23.3 - 27.9)*
+
 27.4 (25.0 - 30.4)*
+#
 <0.0001 
WHR, Median (IQR)   0.92 (0.87 - 0.97) 0.89 (0.84 - 0.94) 0.90 (0.85 - 0.95) 0.91 (0.87 - 0.97)*+ 0.94 (0.90 - 0.98)*+# <0.0001 
Neck circumference, Median (IQR) 37.0 (33.5 - 39.8) 34.0 (32.0 - 37.5) 35.0 (33.0 - 38.5) 37.0 (34.0 - 39.0)*
+
 38.0 (35.0 - 41.0)*
+#
 <0.0001 
Hypertension, % (n) 40.8 (846) 24.3 (111) 34.7 (115) 37.4 (165) 53.9 (455)* <0.0001 
Type 2 diabetes, % (n) 9.7 (200) 3.3 (15) 5.4 (18) 6.8 (30) 16.2 (137)* <0.0001 
Metabolic syndrome, % (n) 30.0 (623) 12.3 (56) 19.3 (64) 27.2 (120) 45.3 (383) <0.0001 
Depression, % (n) 6.2 (107) 6.3 (23) 4.6 (13) 6.6 (25) 6.6 (46) 0.668 
Antihypertensive medication, % (n) 25.7 (532) 14.5 (66) 19.9 (66) 21.5 (95) 36.1 (305)* <0.0001 
Antidepressant medication, %  (n) 5.7 (115) 7.1 (31) 3.4 (11) 4.6 (20) 6.4 (53) 0.096 
Benzodiazepines, % (n) 8.4 (171) 7.4 (33) 8.5 (28) 8.1 (35) 8.9 (75) 0.815 
Current smoking, %, (n) 18.5 (379) 20.3 (92) 18.3 (60) 17.8 (78) 17.9 (149) 0.063 
Alcohol consumption before PSG, mean (SD) 0.45 (0.89) 0.42 (0.82) 0.43 (0.82) 0.40 (0.88) 0.49 (0.93) 0.276 
Alcohol consumption weekly, mean (SD) 6.5 (7.9) 5.5 (7.2) 5.8 (6.9) 6.7 (8.2) 7.1 (8.4)* 0.007 
TST, min, Median (IQR) 406.5 (364.0 - 449.6) 409.2 (370.6 - 453.5) 411.5 (370.5 - 454.0) 415.0 (367.3 - 457.3) 397.5 (353.9 - 441.5)*
+#
 <0.0001 
TST in supine, min, Median (IQR) 120.4 (53.4 - 196.1) 105.4 (49.0 - 174.3) 125.6 (62.5 - 194.6)* 127.5 (58.4 - 187.0) 122.6 (49.6 - 209.3) 0.040 
REM time in supine, min, Median (IQR) 20.0 (2.0 - 44.2) 17.1 (0 - 42.2) 20.0 (3.1 - 47.0) 20.5 (2.1 - 40.5) 21.4 (2.9 - 46.4) 0.094 
REM time, % of TST, Median (IQR)  22.5 (18.6 - 26.1) 23.6 (19.9 - 27.0) 23.0 (19.9 - 26.3) 22.9 (19.3 - 26.2) 21.1 (17.2 - 25.4)*+# <0.0001 
SWS time, % of TST, Median (IQR)  19.4 (14.2 - 25.0) 20.8 (16.3 - 25.8) 20.0 (15.3 - 25.6) 19.8 (14.3 - 25.7) 18.0 (12.5 - 23.9)*+# <0.0001 
Arousal index, events/h, Median (IQR) 18.7 (13.8 - 25.9) 14.2 (10.4 - 19.7)* 17.1 (13.6 - 22.0)* 18.1 (14.1 - 23.8)* 23.2 (16.6 - 31.1)*
+#
 <0.0001 
Total AHI, events/h, Median (IQR)  9.8 (4.2 - 20.1) 2.0 (1.0 - 4.8) 4.3 (2.9 - 8.1)* 9.0 (6.0 - 13.5)*+ 21.4 (13.9 - 34.5)*+# <0.0001 
NREM-AHI, events/h, Median (IQR)  7.4 (2.3 - 17.2) 1.7 (0.6 - 5.0) 3.4 (1.4 - 7.8)* 6.6 (3.0 - 12.0)*+ 16.6 (8.3 - 30.1)*+# <0.0001 
REM-AHI, events/h, Median (IQR) 15.3 (5.7 - 30.3) 2.2 (0.9 - 3.4) 7.1 (6.0 - 8.6)* 14.5 (12.4 - 16.8)*
+
 34.4 (25.7 - 46.8)*
+#
 <0.0001 
REM-AHI non-supine, events/h, Median (IQR) 8.8 (2.6 – 23.0) 1.3 (0 – 2.7) 5.1 (2.2 – 7.3)* 10.4 (6.2 – 14.3)*
+
 26.7 (18.2 – 40.9)*
+#
 <0.0001 
REM-AHI supine, events/h, Median (IQR) 27.9 (8.4 - 52.7) 2.7 (0 - 6.2) 10.8 (7.0 - 23.4)* 25.1 (16.4 - 42.5)*
+
 52.2 (37.5 - 68.6)*
+#
 <0.0001 
ODI 3%, events/h, Median (IQR) 9.9 (4.3 - 19.0) 2.4 (1.0 - 5.5) 4.7 (3.0 - 9.0)* 8.7 (5.6 - 14.3)*
+
 19.8 (12.9 - 30.9)*
+#
 <0.0001 
T90, % of TST, mean (SD) 4.1 (12.3) 7.2 (1.1) 9.3 (1.4)* 13.0 (3.5)*
+
 14.3 (7.0)*
+#
 <0.0001 
ESS score, Median (IQR) 6.0 (3.0 - 9.0) 6.0 (3.0 - 8.0) 5.0 (3.0 - 9.0) 6.0 (3.8 - 8.0) 6.0 (3.0 - 9.0) 0.690 
Definition of abbreviations: AHI = apnoea–hypopnoea index; BMI = body mass index; ESS = Epworth Sleepiness Scale; IQR = interquartile range; Min = minutes; NREM = non-rapid eye movement; ODI = 
oxygen desaturation index per hour of 3% or greater; PSG = polysomnography; REM = rapid eye movement; SD = standard deviation; SWS = slow wave sleep; T90 = percentage of total sleep time with 
oxygen saturation below 90%; TST = total sleep time; WHR = waist-to-hip ratio. Alcohol consumption = mean consumption of standard drink containing 10 g of alcohol.  
Data analyzed by Pearson’s chi-square or Kruskal-Wallis followed by Mann-Whitney pairwise comparisons. *p<0.008 compared to <5/h; #p<0.008 compared to 10-19.9/h; +p<0.008 compared to 5-9.9/h. 
Number of participants with missing data: alcohol consumption before PSG (31), antidepressant medication (49), benzodiazepines (27), BMI (12), smoking (22), depression (353), diabetes (2), 
hypertension (2), neck circumference (57), REM-AHI non-supine (89), REM-AHI supine (394), REM time in supine (1), T90 (28), WHR (2). 
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 Table 2. Patient characteristics in NREM-AHI<10 subgroup based on REM-AHI severity. 
REM-AHI severity categories in NREM-AHI<10 subgroup 
  All <5/h 5-9.9/h 10-19.9/h ≥20/h p-value 
Number of subjects, % (n) 100 (1241) 33.2 (412) 22.2 (275) 23.4 (291) 21.2 (263)   
Female, % (n) 63.7 (790) 73.5 (303)* 60.7 (167) 58.8 (171) 56.7 (149) <0.0001 
Age, years, Median (IQR) 53.5 (46.7 - 63.2) 50.5 (45.3 - 58.4) 53.8 (46.5 - 62.7)* 54.4 (48.0 - 64.7)* 57.7 (49.2 - 66.7)*
+
 <0.0001 
BMI, kg/m
2
, Median (IQR) 24.7 (22.3 - 27.3) 23.4 (21.3 - 26.1) 23.9 (21.9 - 26.2) 25.4 (22.9 - 27.5)*
+
 26.4 (24.3 - 29.5)*
+#
 <0.0001 
WHR, Median (IQR)   0.90 (0.85 - 0.95) 0.89 (0.84 - 0.93) 0.89 (0.84 - 0.94) 0.90 (0.86 - 0.95)* 0.92 (0.87 - 0.96)*+ <0.0001 
Neck circumference, Median (IQR) 35.0 (33.0 - 38.0) 34.0 (32.0 - 37.0) 35.0 (33.0 - 38.0)* 36.0 (33.0 - 38.0)* 36.5 (34.5 - 39.0)*
+#
 <0.0001 
Hypertension, % (n) 32.1 (398) 22.3 (92) 32.7 (90) 33.7 (98) 45.0 (118)* <0.0001 
Type 2 diabetes, % (n) 5.4 (67) 2.2 (9) 3.6 (10) 5.5 (16) 12.2 (32)* <0.0001 
Metabolic syndrome, % (n) 20.7 (257) 10.7 (44) 17.1 (47) 22.0 (64) 38.8 (102)* <0.0001 
Depression, % (n) 7.0 (72) 6.6 (22) 5.4 (13) 7.3 (18) 8.8 (19) 0.547 
Antihypertensive medication, % (n) 18.7 (232) 11.9 (49) 18.5 (51) 18.6 (54) 29.7 (78) <0.0001 
Antidepressant medication, %  (n) 4.7 (57) 6.8 (27) 3.7 (10) 4.2 (12) 3.1 (8) 0.100 
Benzodiazepines, % (n) 7.5 (92) 6.2 (25) 9.2 (25) 5.9 (17) 9.6 (25) 0.192 
Current smoking, %, (n) 20.0 (246) 20.3 (83) 19.5 (53) 19.7 (57) 20.3 (53) 0.832 
Alcohol consumption before PSG, mean (SD) 0.41 (0.84) 0.40 (0.79) 0.45 (0.90) 0.34 (0.76) 0.47 (0.93) 0.422 
Alcohol consumption weekly, mean (SD) 5.7 (7.3) 5.3 (7.1) 5.8 (7.1) 6.1 (7.2) 5.9 (7.8) 0.380 
TST, min, Median (IQR) 409.5 (367.0 - 453.5) 411.3 (372.0 - 455.1) 411.9 (366.5 - 456.5) 419.0 (374.5 - 458.3) 394.5 (351.5 - 438.5)*
+#
 0.001 
TST in supine, min, Median (IQR) 122.3 (55.6 - 192.0) 110.0 (53.0 - 183.6) 133.0 (62.5 - 198.5) 128.9 (56.9 - 185.5) 128.8 (47.1 - 212.4) 0.148 
REM time in supine, min, Median (IQR) 94.5 (76.3 - 114.0) 21.2 (0.5 - 46.5) 23.6 (6.0 - 51.5) 25.0 (7.0 - 46.5) 28.5 (7.5 - 52.0)* 0.028 
REM time, % of TST, Median (IQR)  23.4 (19.7 - 26.8) 23.8 (20.3 - 27.2) 23.5 (20.2 - 26.3) 23.3 (19.4 - 26.8) 22.3 (17.8 - 26.2)* 0.018 
SWS time, % of TST, Median (IQR)  20.8 (16.1 - 26.0) 21.0 (16.7 - 26.0) 20.3 (15.6 - 25.9) 20.9 (15.7 - 25.9) 20.9 (16.0 - 26.1) 0.686 
Arousal index, Median (IQR) 15.3 (11.8 - 20.5) 13.8 (10.1 - 18.5) 16.5 (12.8 - 21.4)* 15.7 (12.9 - 20.5)* 16.5 (12.5 - 22.6)* <0.0001 
Total AHI, events/h, Median (IQR)  5.3 (2.4 - 8.7) 1.8 (0.9 - 3.4) 3.7 (2.8 - 6.0)* 6.6 (5.2 - 9.0)*+ 11.1 (8.9 - 13.5)*+# <0.0001 
NREM-AHI, events/h, Median (IQR)  3.1 (1.3 - 6.1) 1.4 (0.5 - 3.5) 2.6 (1.2 - 5.2)* 4.2 (2.0 - 6.5)*+ 5.6 (3.5 - 7.7)*+# <0.0001 
REM-AHI, events/h, Median (IQR) 8.6 (3.4 - 17.8) 2.1 (0.9 - 3.4) 7.1 (6.0 - 8.5)* 14.2 (12.2 - 16.5)*
+
 28.2 (13.5 - 30.2)*
+#
 <0.0001 
REM-AHI non-supine, events/h, Median (IQR) 4.7 (1.3 – 12.5) 1.2 (0 – 2.6) 5.0 (2.2 – 7.2)* 10.0 (5.6 – 14.0)*
+
 22.2 (23.5 - 35.3)*
+#
 <0.0001 
REM-AHI supine, events/h, Median (IQR) 15.0 (4.3 - 33.3) 2.7 (0 - 5.9) 10.6 (6.9 - 20.5)* 23.0 (15.9 - 37.4)*
+
 41.2 (31.3 - 53.6)*
+#
 <0.0001 
ODI 3%, events/h, Median (IQR) 5.3 (2.6 - 9.0) 2.0 (1.0 - 4.2) 4.2 (2.7 - 6.2)* 6.6 (4.7 - 8.9)*
+
 11.0 (8.8 - 14.2)*
+#
 <0.0001 
T90, % of TST, mean (SD) 2.5 (11.1) 1.1 (7.6) 1.5 (10.1) 2.9 (13.7)*
+
 5.2 (13.0)*
+#
 <0.0001 
ESS score, Median (IQR) 6.0 (3.0 - 9.0) 6.0 (3.0 - 8.0) 5.0 (3.0 - 9.0) 6.0 (3.3 - 8.0) 6.0 (4.0 - 9.0) 0.344 
Definition of abbreviations: AHI = apnoea–hypopnoea index; BMI = body mass index; ESS = Epworth Sleepiness Scale; IQR = interquartile range; Min = minutes; NREM = non-rapid eye movement; ODI = 
oxygen desaturation index per hour of 3% or greater; PSG = polysomnography; REM = rapid eye movement; SD = standard deviation; SWS = slow wave sleep; T90 = percentage of total sleep time with 
oxygen saturation below 90%; TST = total sleep time; WHR = waist-to-hip ratio. Alcohol consumption = mean consumption of standard drink containing 10 g of alcohol.  
Data analyzed by Pearson’s chi-square or Kruskal-Wallis followed by Mann-Whitney pairwise comparisons. *p<0.008 compared to <5/h; #p<0.008 compared to 10-19.9/h; +p<0.008 compared to 5-9.9/h.  
Number of participants with missing data: alcohol consumption before PSG (20), antidepressant medication (28), benzodiazepines (16), BMI (3), smoking (9), depression (206), hypertension (1), neck 
circumference (35), REM-AHI non-supine (44), REM-AHI supine (213), T90 (14), WHR (1). 
Page 18 of 53European Respiratory Journal
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 Table 3. Patient characteristics in AHI<10 subgroup based on REM-AHI severity. 
REM-AHI severity categories in AHI<10 subgroup 
  All <5/h 5-9.9/h 10-19.9/h ≥20/h p-value 
Number of subjects, % (n) 100 (1047) 40 (419) 26.3 (275) 24.6 (258) 9.1 (95)   
Female, % (n) 65.2 (683) 72.8 (305)* 61.5 (169) 59.3 (153) 58.9 (56) <0.0001 
Age, years, Median (IQR) 52.8 (46.2 - 62.4) 50.5 (45.4 - 58.5) 53.8 (46.5 - 63.0)* 54.4 (48.0 - 64.3)* 55.0 (47.2 - 66.1)* <0.0001 
BMI, kg/m
2
, Median (IQR) 24.3 (21.9 - 26.8) 23.4 (21.3 - 26.1) 24.0 (21.9 - 26.3) 25.3 (22.7 - 27.3)*
+
 26.3 (23.6 - 30.4)*
+#
 <0.0001 
WHR, Median (IQR)   0.90 (0.85 - 0.94) 0.89 (0.84 - 0.94) 0.89 (0.84 - 0.94) 0.90 (0.86 - 0.95)* 0.92 (0.87 - 0.97)*+ <0.0001 
Neck circumference, Median (IQR) 35.0 (33.0 - 38.0) 34.0 (32.0 - 37.0)* 35.0 (33.0 - 38.0)* 35.5 (33.0 - 38.0)* 36.0 (34.4 - 39.0)*
+
 <0.0001 
Hypertension, % (n) 29.8 (312) 22.9 (96) 32.4 (89) 33.7 (87) 42.1 (40)* <0.0001 
Type 2 diabetes, % (n) 4.3 (45) 2.4 (10) 3.6 (10) 5.4 (14) 11.6 (11)* 0.001 
Metabolic syndrome, % (n) 17.9 (187) 11.5 (48) 17.1 (47) 21.3 (55) 17.9 (187)* <0.0001 
Depression, % (n) 6.4 (56) 6.5 (22) 5.4 (13) 7.2 (16) 6.3 (5) 0.887 
Antihypertensive medication, % (n) 16.9 (177) 12.2 (51) 18.2 (50) 19.0 (49) 28.4 (27)* 0.001 
Antidepressant medication, %  (n) 4.9 (50) 6.9 (28) 3.7 (10) 4.3 (11) 1.1 (1) 0.058 
Benzodiazepines, % (n) 7.7 (79) 6.1 (25) 9.2 (25) 6.3 (16) 13.8 (13)* 0.045 
Current smoking, %, (n) 20.9 (217) 20.7 (86) 19.5 (53)* 21.8 (56)* 23.2 (22)*
+
 0.858 
Alcohol consumption before PSG, mean (SD) 0.40 (0.81) 0.39 (0.78) 0.45 (0.90) 0.35 (0.79) 0.41 (0.78) 0.511 
Alcohol consumption weekly, mean (SD) 5.7 (7.2) 5.4 (7.3) 5.8 (7.1) 6.0 (7.3) 5.6 (6.7) 0.497 
TST, min, Median (IQR) 411.0 (368.5 - 454.0) 410.5 (372.0 - 455.5) 411.5 (366.5 - 458.0) 418.8 (371.9 - 353.0) 391.5 (353.0 - 420.4)*
+#
 0.002 
TST in supine, min, Median (IQR) 121.2 (55.4 - 190.0) 109.9 (49.3 - 177.5) 133.0 (62.5 - 200.0) 127.9 (54.3 - 187.0) 131.2 (47.0 - 189.1) 0.111 
REM time in supine, min, Median (IQR) 23.2 (3.1 - 48.0) 20.6 (0.2 - 46.0) 23.6 (6.0 - 51.1) 25.0 (7.3 - 46.4) 27.8 (6.0 - 57.5) 0.062 
REM time, % of TST, Median (IQR)  23.3 (19.7 - 26.6) 23.8 (20.3 - 27.2) 23.5 (20.2 - 26.3) 23.2 (19.4 - 26.6) 20.4 (17.0 - 23.6)*+# <0.0001 
SWS time, % of TST, Median (IQR)  20.8 (16.3 - 25.9) 20.9 (16.6 - 25.9) 20.1 (15.6 - 25.9) 20.6 (15.6 - 25.9) 22.3 (18.0 - 26.1) 0.237 
Arousal index, Median (IQR) 15.2 (11.5 - 20.0) 13.8 (10.2 - 18.6) 16.5 (12.8 - 21.4)* 15.5 (12.8 - 20.1)* 15.7 (12.0 - 21.6)* <0.0001 
Total AHI, events/h, Median (IQR)  4.2 (2.1 - 6.9) 1.8 (0.9 - 3.5) 3.7 (2.8 - 6.0)* 6.3 (5.1 - 8.3)*+ 8.1 (6.9 - 9.2)*+# <0.0001 
NREM-AHI, events/h, Median (IQR)  2.4 (1.1 - 4.9) 1.5 (0.5 - 3.6) 2.6 (1.2 - 5.2)* 3.7 (1.9 - 5.7)*+ 3.2 (2.0 - 4.2)* <0.0001 
REM-AHI, events/h, Median (IQR) 6.5 (2.7 - 12.7) 2.1 (0.9 - 3.4) 7.0 (6.0 - 8.5)* 13.9 (12.0 - 16.4)*
+
 24.7 (21.7 - 28.3)*
+#
 <0.0001 
REM-AHI non-supine, events/h, Median (IQR) 3.5 (1.0 – 8.6) 1.2 (0 – 2.6) 5.0 (2.2 – 7.2)* 10.0  (5.5 – 13.6)*
+
 20.5 (7.0 – 26.4)*
+#
 <0.0001 
REM-AHI supine, events/h, Median (IQR) 10.6 (3.0 - 24.1) 2.7 (0 - 5.9) 10.6 (7.0 - 20.5)* 22.3 (15.2 - 35.1)*
+
 31.8 (25.8 - 46.0)*
+#
 <0.0001 
ODI 3%, events/h, Median (IQR) 4.4 (2.2 - 7.0) 2.0 (1.0 - 4.4) 4.2 (2.7 - 6.2) 6.2 (4.5 - 8.2)*
+
 8.4 (6.9 - 10.2)*
+#
 <0.0001 
T90, % of TST, mean (SD) 2.1 (11.1) 1.1 (7.5) 1.5 (10.1) 2.9 (14.3)*
+
 5.6 (15.7)*
+#
 <0.0001 
ESS score, Median (IQR) 6.0 (3.0 - 9.0) 6.0 (3.0 - 8.0) 5.0 (3.0 - 9.0) 5.0 (3.5 - 8.5) 6.0 (3.0 - 9.0) 0.906 
Definition of abbreviations: AHI = apnoea–hypopnoea index; BMI = body mass index; ESS = Epworth Sleepiness Scale; IQR = interquartile range; Min = minutes; NREM = non-rapid eye movement; ODI = 
oxygen desaturation index per hour of 3% or greater; PSG = polysomnography; REM = rapid eye movement; SD = standard deviation; SWS = slow wave sleep; T90 = percentage of total sleep time with 
oxygen saturation below 90%; TST = total sleep time; WHR = waist-to-hip ratio. Alcohol consumption = mean consumption of standard drink containing 10 g of alcohol.  
Data analyzed by Pearson’s chi-square or Kruskal-Wallis followed by Mann-Whitney pairwise comparisons. *p<0.008 compared to <5/h; #p<0.008 compared to 10-19.9/h; +p<0.008 compared to 5-9.9/h.  
Number of participants with missing data: alcohol consumption before PSG (19), antidepressant medication (27), benzodiazepines (15), BMI (3), smoking (7), depression (169), neck circumference (33), 
NREM-AHI supine (58), REM-AHI supine (194), T90 (12), WHR (1).
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Table 4. Associations between REM-AHI and blood pressure. 
 
 
  
Entire cohort 
NREM-AHI<10 
subgroup 
AHI<10 
subgroup 
β p-value β p-value β p-value 
Systolic blood pressure             
REM-AHI (continuous) 0.03 0.167 0.01 0.842 -0.03 0.671 
5-9.9/h 2.02 0.070 1.28 0.275 1.43 0.213 
10-19.9/h 2.11 0.051 1.80 0.135 1.61 0.181 
≥20/h 2.40 0.030 0.50 0.701 -1.18 0.486 
Diastolic blood pressure             
REM-AHI (continuous) 0.02 0.208 0.01 0.821 -0.02 0.636 
5-9.9/h 1.27 0.089 1.01 0.193 1.02 0.179 
10-19.9/h 1.20 0.097 1.12 0.159 0.90 0.255 
≥20/h 1.72 0.020 0.23 0.787 -1.19 0.289 
Definition of abbreviations: AHI = apnoea–hypopnoea index; β = linear regression coefficient beta; NREM = non-rapid 
eye movement; REM = rapid eye movement. 
Data analyzed by linear regression using REM-AHI as continuous or dummy variable with adjustment for age, sex, body 
mass index, waist-to-hip ratio, total sleep time, smoking, alcohol consumption (weekly), antihypertensive drug and log-
NREM-AHI. 
Number of participants with missing data in the models (entire cohort, NREM-AHI<10, AHI<10): systolic blood pressure 
and diastolic blood pressure (16, 6, 5). 
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Figure captions 
Figure 1. Odds ratios and 95% confidence intervals (CI) for rapid eye movement (REM) 
apnoea-hypopnoea index (AHI) severity categories in the entire cohort (n=2074 
polysomnographies). Circles represent the odds ratio and bars the 95% CI. Logistic 
regression models fitted to examine the associations for the entire cohort with metabolic 
syndrome, diabetes, hypertension and depression. Increasing REM-AHI severity was 
significantly associated with metabolic syndrome. Hypertension, diabetes and depression 
were not significantly associated with REM-sleep-disordered breathing (REM-SDB). 
Cardiovascular and metabolic comorbidities were adjusted for age, sex, body mass index, 
waist-to-hip ratio, total sleep time, smoking, alcohol consumption (weekly) and the logarithme 
of non-REM-AHI (log-NREM-AHI). Depression was adjusted for age, gender, and 
consumption of benzodiazepines, antidepressants, and log-NREM-AHI. Number of 
participants with missing data in the models: metabolic syndrome (35), diabetes (37), 
hypertension (37), depression (389).  
 
Figure 2. Odds ratios and 95% confidence intervals (CI) for rapid eye movement (REM) 
apnoea-hypopnoea index (AHI) severity categories in the subgroup with non-REM-
AHI<10/h (n=1241 polysomnographies). Circles represent the odds ratio and bars the 95% 
CI. Logistic regression models fitted to examine the associations for the entire cohort with 
metabolic syndrome, diabetes, hypertension and depression. Increasing REM-AHI severity 
was significantly associated with metabolic syndrome and diabetes. Hypertension and 
depression showed no association with REM-sleep-disordered breathing (REM-SDB). 
Cardiovascular and metabolic comorbidities were adjusted for age, sex, body mass index, 
waist-to-hip ratio, total sleep time, smoking, alcohol consumption (weekly) and the logarithme 
of non-REM-AHI (log-NREM-AHI). Depression was adjusted for age, gender, and 
consumption of benzodiazepines, antidepressants, and log-NREM-AHI. Number of 
participants with missing data in the models: metabolic syndrome (13), diabetes (13), 
hypertension (14), depression (226). 
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Figure 3. Odds ratios and 95% confidence intervals (CI) for rapid eye movement (REM) 
apnoea-hypopnoea index (AHI) severity categories in the subgroup with total AHI<10/h 
(n=1047 polysomnographies). Circles represent the odds ratio and bars the 95% CI. 
Logistic regression models fitted to examine the associations for the entire cohort with 
metabolic syndrome, diabetes, hypertension and depression. Moderate-to-severe REM 
sleep-disordered breathing (REM-SDB) was significantly associated with metabolic 
syndrome and diabetes. Diabetes, hypertension and depression showed no association with 
REM-SDB. Cardiovascular and metabolic comorbidities were adjusted for age, sex, body 
mass index, waist-to-hip ratio, total sleep time, smoking, alcohol consumption (weekly) and 
the logarithme of non-REM-AHI (log-NREM-AHI). Depression was adjusted for age, gender, 
and consumption of benzodiazepines, antidepressants, and log-NREM-AHI. Number of 
participants with missing data in the models: metabolic syndrome (11), diabetes (11), 
hypertension (11), depression (189). 
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“Take Home” Message: REM sleep-disordered breathing is highly prevalent and is 
associated with metabolic syndrome and diabetes. 
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 ABSTRACT 
Study Objectives: This study determined the prevalence of rapid eye movement-related 
sleep-disordered breathing (REM-SDB) in the general population, and investigated the 
associations of REM-SDB with hypertension, metabolic syndrome, diabetes and depression. 
Methods: 2074 home polysomnography (PSG) recordings from the population-based 
HypnoLaus Sleep Cohort (48.3% men, 57±11 years old) were analysed. The apnoea–
hypopnoea index was measured during REM (REM-AHI) and non-REM (NREM-AHI) sleep. 
Regression models were used to explore the association between REM-SDB and 
hypertension, diabetes, metabolic syndrome and depression in the entire cohort and in 
subgroups with NREM-AHI<10/h and total AHI<10/h. 
Results: Prevalence of REM-AHI≥20/h was 40.8% in the entire cohort. An association 
between increasing REM-AHI and metabolic syndrome was found in the entire cohort and 
in both subgroups (p-trend=0.014, <0.0001 and 0.015, respectively). An association was 
also found between REM-AHI≥20/h and diabetes in both NREM-AHI<10/h (OR=3.12 [1.35-
7.20]) and AHI<10/h (OR=2.92 [1.12-7.63]) subgroups. Systolic and diastolic blood 
pressure were positively associated with REM-AHI≥20/h. 
Conclusions: REM-SDB is highly prevalent in our middle-to-older age sample and is 
independently associated with metabolic syndrome and diabetes. These findings suggest 
that an increase in REM-AHI could be clinically relevant. 
 
Keywords: REM, sleep apnea, sleep-disordered breathing, metabolic syndrome, diabetes, 
depression, hypertension. 
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 Introduction 
Sleep-disordered breathing (SDB) is highly prevalent in the general population [1], 
causing intermittent hypoxaemia, microarousals, sleep fragmentation, and acute changes in 
blood pressure and heart rate. SDB during rapid eye movement sleep (REM-SDB) is 
estimated to occur in 10–36% of patients with SDB [2], but its prevalence in the general 
population is not yet known.  
REM-SDB is more common in patients with mild and moderate SDB [3] and has a 
higher prevalence in younger women than in men [4]. Data about sleepiness and REM-SDB 
are conflicting, but studies found no association between REM-SDB and daytime 
sleepiness or reduced quality of life [5-8]. 
Nocturnal respiratory events are usually more frequent and of longer duration in 
REM compared with NREM sleep, probably due to greater pharyngeal muscle relaxation [9-
11] and a reduction in the hypoxic and hypercapnic ventilatory response throughout REM 
sleep [12, 13]. 
Along with intermittent hypoxia, elevated sympathetic activity is thought to be the 
most important mechanism underlying the increased cardiovascular risk associated with 
SDB [14]. Compared with NREM sleep, REM sleep is associated with higher sympathetic 
activity and cardiovascular instability [15-17]. Recent studies have shown an association 
between REM-SDB and non-dipping nocturnal blood pressure and hypertension [18-20], 
and REM-SDB has further been reported to have an adverse effect on long-term glycaemic 
control and insulin resistance [21, 22]. However, the specific impact of REM-SDB on 
cardiovascular risk factors and psychiatric comorbidities is not yet known. 
This study evaluated the prevalence of REM-SDB in the general population and 
investigated the associations between REM-SDB and cardiovascular, metabolic and 
psychiatric comorbidities. 
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 Methods 
Population sample 
The HypnoLaus Sleep Cohort study has been described previously [1]. It included a 
random subset of the population-based CoLaus/PsyCoLaus cohort [23, 24] who underwent 
full polysomnography (PSG) at home and answered questionnaires about their sleep 
complaints, including the Epworth Sleepiness Scale (ESS) [25]. The ethics committee of the 
University of Lausanne approved the CoLaus/PsyCoLaus cohort study and the HypnoLaus 
Sleep Cohort study. Written informed consent was obtained from all participants. 
 
Sleep data analysis 
PSG was performed by certified technicians who equipped participants with a 
polysomnographic recorder (Titanium, Embla Flaga, Reykjavik, Iceland) in accordance with 
2007 American Academy of Sleep Medicine (AASM) recommended setup specifications 
[26] at the Center for Investigation and Research in Sleep (CIRS) at the University Hospital 
of Lausanne. All PSGs took place in the patients’ home environment. Sleep stages were 
scored in 30-second epochs according to the 2007 AASM criteria [27]. Apnoeas, 
hypopnoeas, and respiratory effort-related arousals were scored according to the 2012 
AASM criteria [28]. 
The average number of apnoeas-hypopnoeas per hour of sleep (apnoea–hypopnoea 
index [AHI]) was calculated for the whole night, and for REM and NREM sleep separately. 
Percentage of total sleep time (TST) with oxygen saturation below 90% (T90) and the 
number of ≥3% oxygen desaturations per hour (oxygen desaturation index [ODI]) were 
assessed. 
Quality control for concordance between the two PSG scorers was implemented 
periodically to ensure that both achieved at least 90% agreement for sleep stages and 
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 respiratory events, and 85% agreement for arousals. An expert sleep clinician reviewed 
every recording and a second sleep expert performed quality checks. We asked individuals 
who were currently receiving treatment for SDB (n=38) to discontinue their treatment 1 
week before the sleep recording. 
 
Outcome variables 
Body weight and height were measured with participants standing without shoes in 
light indoor clothes. Body weight was measured in kilograms to the nearest 100g using a 
Seca® scale, which was calibrated regularly. Height was measured to the nearest 5 mm 
using a Seca® height gauge. Body mass index (BMI) was calculated as weight (kg)/height 
(m2). 
Waist was measured with a non-stretchable tape over the unclothed abdomen at the 
narrowest point between the lowest rib and the iliac crest. Hip was measured at the largest 
part of the hips. For waist and hip, two measures were made and the mean (expressed in 
centimeters) was used to assess waist-to-hip ratio (WHR). Neck circumpherence was 
measured at the middle of the neck between the mid-cervical spine and superior line of the 
cricothyroid membrane. 
Blood pressure was measured thrice on the left arm in the morning and the average 
of the last two readings was considered. Arterial hypertension was defined as systolic blood 
pressure ≥140 mmHg, diastolic blood pressure ≥90 mmHg, or current use of 
antihypertensive drugs. Diabetes was defined as fasting blood glucose ≥7 mmol/L or 
current antidiabetic drug treatment. Metabolic syndrome was defined according to the Adult 
Treatment Panel III (ATP-III) report [29]. Smoking status, alcohol consumption and the 
number of alcoholic drinks taken before the PSG recording and weekly were self-reported. 
The semi-structured Diagnostic Interview for Genetic Studies (DIGS) was used to diagnose 
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 current major depressive disorder, which was defined according to criteria of the Diagnostic 
and Statistical Manual of Mental Disorders, 4th edition (DSM-IV) [30].  Interviewers were 
required to be masters-level psychologists, and were trained over a two-month period. 
During data collection, each interview was reviewed by an experienced senior clinical 
psychologist. The DIGS interview systematically assesses the last and the most severe 
depressive episodes.  
 
Statistical analysis 
All statistical analyses were performed with IBM SPSS version 21.0 (IBM 
Corporation, Armonk, NY, USA). Bivariate analyses were performed using Chi-squared test 
for categorical variables and Kruskal-Wallis for continuous variables. Pairwise comparisons 
were performed using Mann-Whitney test with Bonferroni’s correction for p-value. Logistic 
regression models were used to estimate the association between REM-SDB and the 
presence of hypertension, diabetes, metabolic syndrome and depression. REM-AHI was 
classified into four severity categories (REM-AHI <5/h [reference group]; 5–9.9/h; 10–
19.9/h; and ≥20/h) for the primary analysis (according to previous results of the HypnoLaus 
cohort) and used as continuous variable for a sensitivity analysis. A linear regression model 
was also used to assess the association between REM-AHI (as continuous and dummy 
variable) and diastolic and systolic blood pressure. 
Analyses were performed on the entire cohort and in two subgroups: one restricted 
to subjects with a total AHI<10/h (absent or mild SDB), and another in those with NREM-
AHI<10/h (exclusive REM-SDB). For hypertension, diabetes and metabolic syndrome, the 
models were adjusted for age, sex, BMI, WHR, TST, logarithme of NREM-AHI (log-NREM-
AHI), smoking and alcohol consumption. An additional adjustment for antihypertensive 
treatment was added when SBP and DBP were used as outcome variables in the linear 
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 regression models. For depression, the model was adjusted for age, sex, and consumption 
of benzodiazepines and antidepressants. Results were expressed as odds ratio (OR) and 
95% confidence interval. Statistical significance was condidered for a two-sided test p<0.05 
and p<0.008 for multiple comparisons in univariate analysis. 
Results 
Study population 
Of the 2168 subjects (48.3% men, 59±11 y.o, range 40-85, body mass index 25.6 ± 
4.1 kg/m2) who underwent complete PSG at home, 60 (3%) had technical problems, 54 
underwent a second recording and six subjects refused resulting in 2162 valid PSG 
recordings. Of these, 41 with less than four hours of TST were excluded to avoid the risk of 
unbalanced representation of different sleep stages. We also excluded 47 patients with <30 
minutes of REM sleep to allow a proper assessment of REM sleep [18, 19]. Therefore, 
2074 PSG recordings were included in the analysis. Clinical and polysomnographic 
characteristics of the total sample are shown in Table 1. 
 
REM-SDB in the entire cohort 
The overall prevalence of moderate-to-severe REM-SDB (REM-AHI ≥20/h) was 
40.8% in HypnoLaus middle-to-older age general population sample. As REM-AHI 
increased, there was a corresponding increase in mean age, BMI, WHR and neck 
circumference as well as in the prevalence of hypertension, diabetes and metabolic 
syndrome (Table 1). Patients in the higher REM-AHI severity categories had lower TST, 
and lower proportions of slow wave sleep (SWS) and REM sleep. They also had higher ODI 
and arousal index and spent more time with oxygen saturation <90% (T90), but there was 
no difference in the ESS score between the REM-SDB severity categories. 
Figure 1 shows the results for the association of REM-SDB with metabolic syndrome, 
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 diabetes, hypertension and depression. REM-AHI categories of 5-9.9/h (OR=1.78 [1.13-
2.81], p=0.013), 10-19.9/h (OR=1.69 [1.12-2.57], p=0.013), and ≥20/h (OR=1.94 [1.29-
2.92], p=0.001) were independently associated with metabolic syndrome, but not diabetes 
and depression. Although we found no association between hypertension and REM-SDB, 
there was a significant association of REM-AHI≥20/h with both systolic and diastolic blood 
pressure (Table 4). 
 
NREM-AHI <10/h (exclusive REM-SDB) 
A subgroup of 1241 subjects (59.8%) with NREM-AHI<10/h was analysed to better 
define the specific influence of REM-SDB (Table 2). In this subgroup, the prevalence of 
moderate-to-severe REM-SDB (REM-AHI≥20/h) was 21.2% (n=263). As in the overall 
analysis, patients in the highest REM-AHI severity categories were older and had higher 
BMI, WHR and neck circumference, and a higher prevalence of hypertension, diabetes and 
metabolic syndrome. 
TST and REM sleep time were reduced only in the REM-AHI≥20/h group, while 
arousal index, ODI and T90 was increased in all REM-SDB subgroups. No significant 
differences were found in SWS time and ESS score among the REM-SDB severity 
categories. 
The same multivariate models were applied to this subgroup (Figure 2). Increasing 
REM-AHI severity was significantly associated with metabolic syndrome and diabetes, 
while hypertension and depression showed no association with REM-SDB. Although the p-
value for trend was not significant for depression, the subgroup with the highest severity of 
REM-SDB (i.e. REM-AHI>20/h) had a trend towards higher odds of depression (OR=2.14 
[0.99-4.64], p=0.054) when compared to the group with no REM-SDB (i.e. REM-AHI<5/h). 
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 Total AHI<10/h (absent or mild SDB) 
 A second subgroup of 1047 subjects (50.5%) with total AHI<10/h was analysed to 
evaluate the prevalence and significance of REM-SDB in subjects with absent or mild SDB 
(Table 3). In this subgroup the prevalence of moderate-to-severe REM-SDB (REM-
AHI≥20/h) was 9.1% (n=95). As observed in the exclusive REM-SDB subgroup and the 
overall population, increasing REM-AHI severity was associated with higher mean age, 
BMI, WHR, neck circumference, and a higher prevalence of metabolic syndrome, diabetes 
and hypertension in univariate analysis. 
Only the REM-AHI≥20/h group presented lower TST and REM sleep time compared 
to the other groups, while all REM-SDB subgroups presented increased arousal index 
compared to REM-AHI<5/h. Subjects with higher REM-AHI showed increased ODI and 
T90. No significant differences were found in SWS time and ESS score across the REM-
AHI categories. 
Figure 3 shows the results of the logistic regression models applied to this subgroup. 
There was a significant association of moderate-to-severe REM-SDB with both metabolic 
syndrome and diabetes, but not hypertension or depression. 
We performed the same analysis using REM-AHI as continuous variable instead of 
REM-AHI categories with the same covariables previously described. Using these models, 
we also found significant associations between REM-AHI and metabolic syndrome in the 
entire cohort and the two subgroups, and with diabetes in both NREM-AHI<10/h and 
AHI<10/h subgroups (Table S1). However, no association was significant for hypertension 
and depression. 
 
Discussion 
To our knowledge, this is the first study demonstrating an independent association of 
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 REM-SDB with metabolic syndrome and diabetes in the general population. We also 
showed in this analysis that the prevalence of moderate-to-severe REM-SDB (REM-
AHI≥20/h) in this middle to older age general population sample was 40.6%, and that nearly 
10% of patients with a global AHI of <10/h have moderate-to-severe REM-SDB. These 
findings may have important implications for routine clinical practice in sleep medicine 
because they suggest that REM-AHI may need to be considered independently from global 
AHI when interpreting PSG results in patients at risk for metabolic dysfunction.  
 
REM-SDB and metabolic syndrome 
Several studies have shown a relationship between SDB and metabolic syndrome [1, 
31, 32], but none of them assessed the relationship with REM-SDB. In the present study, 
there was a clear and independent association between increasing REM-AHI severity and 
the presence of metabolic syndrome. This association was found in the whole sample as 
well as in subjects with absent or mild SDB (AHI<10/h) and in those with exclusive REM-
SDB (NREM-AHI<10/h). This suggests that apnoeas and hypopnoeas occurring during 
REM sleep may have a specific association with the metabolic syndrome. 
 
REM-SDB and diabetes 
Previous studies showed an association between REM-AHI severity and increasing 
levels of glycosylated haemoglobin (HbA1c) in patients with type 2 diabetes (T2DM) and 
with insulin resistance [21, 22]. In the present study we found a significant and independent 
association between diabetes and REM-SDB in both subgroups with NREM-AHI<10/h and 
AHI<10/h. Recently, Mokhlesi et al described an improvement in glycaemic control in 
patients with T2DM and SDB after one week of 8-hour nightly continuous positive airway 
pressure (CPAP) [33]. However, another study, in which CPAP was used for a mean of 4.3 
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 hours per night, showed no significant improvement in glycaemic control in patients with 
T2DM and SDB [34]. The better results obtained by Mokhlesi and colleagues could be 
related to the longer duration of CPAP usage resulting in better control of REM-SDB, 
because REM sleep mainly occurs toward the end of the night. We can thus speculate that 
the negative results reported by previous studies with shorter CPAP usage (usually limited 
to the first hours of the night) may be due to insufficient treatment of REM-SDB in the 
second part of the night. The importance of longer nightly CPAP use was also recently 
suggested by the results of the SAVE study where a significant decrease in 
cerebrovascular events was present only in patients with moderate-to-severe sleep apnoea 
and coronary or cerebrovascular disease who used CPAP for more than four hours per 
night [34, 35]. It is howerver unclear why this association was found mainly in the group 
with NREM-AHI<10 in our study. 
Different hypotheses can be proposed regarding the underlying mechanisms of the 
associations between REM-SDB and metablic syndrome or diabetes. First, it is well 
established that respiratory events occurring during REM sleep have a longer duration and 
generate greater oxygen desaturations compared to NREM events [9-11]. This may trigger 
increased oxidative stress compared with other respiratory events, which could promote 
metabolic syndrome and diabetes. Acute intermittent hypoxia was also shown to acutely 
increase insulin resistance in healthy volunteers [36]. In addition, compared to NREM sleep, 
sympathetic activity is greater during REM sleep and most endocrine organs implicated in 
glucose metabolism are sensitive to changes in sympathovagal balance [37-39]. 
Furthermore, SDB in REM reversed the physiological nocturnal decline of interstitial 
glucose concentration (IGC), while NREM-SDB had no effect on IGC [40]. Lastly, nocturnal 
hyperglycaemia associated with SDB in patients with diabetes was shown to be specifically 
accentuated during REM sleep [41]. 
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REM-SDB and hypertension 
We previously reported a significant association between SDB severity and 
hypertension in the population-based HypnoLaus sleep cohort [1]. Considering that two 
studies have shown a specific association between REM-SDB and increased incident 
hypertension [18, 19], we tested this association in our sample using a cross-sectional 
analysis. Surprisingly, there was no significant association between REM-SDB and 
hypertension in the whole sample nor in the subgroups with REM-AHI<10/h or global 
AHI<10/h. The reason for these differences between our and previous studies is unclear. In 
the Wisconsin cohort, the scoring of hypopnoeas required a 4% oxygen desaturation, which 
may have selected more severe respiratory events [42]. However, the MAILES study, which 
also found a significant association between REM-SDB and hypertension, used the 
currently recommended 3% criteria for scoring hypopnoeas [19]. Another difference is that 
the MAILES study included only males, whereas we included both genders in our analysis. 
However, this is unlikely to explain the lack of association we found because our models 
were also negative when we restricted the analysis to men (data not shown). The analysis 
by Mokhlesi and colleagues on the Wisconsin cohort used 24-hour blood pressure 
monitoring while we used three measurements in the morning. Although this is a potential 
source of difference between the two studies, the MAILES study used the same technique 
as in the present study and found a significant association between REM-SDB and 
hypertension. When using blood pressure as a continuous dependent variable, there was 
however a significant positive association between moderate-to-severe REM-AHI and both 
systolic and diastolic blood pressure. These findings appear to suggest a possible positive 
association between REM-SDB and blood pressure. 
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 REM-SDB and depression 
We did not find a significant association between depression and REM-SDB, besides 
a trend in the NREM-AHI<10/h subgroup. Our group and others have previously shown that 
patients with SDB are at higher risk of depressive disorders [1, 43-45] and have a greater 
prevalence of other psychiatric comorbidities [46-48]. However, the mechanisms underlying 
the possible association between REM-SDB and depression are not clear. Oxygen 
desaturation and hypoxia during sleep have been proposed as potential mechanisms for 
this association because interventional studies using oxygen or CPAP therapies [49, 50] 
found that reversing hypoxaemia in SDB improved mood disorders. Moreover, due to its 
likely role in emotion processing, REM sleep fragmentation could have a negative impact 
on mood [51]. However, we did not find an independent association of depression with ODI, 
T90, and arousal index (data not shown).  
 
Strengths and limitations 
The main strength of this study is the inclusion of a large sample representative of 
the general population and the extensive phenotyping of participants, which allowed the 
creation of models controlling for the main confounding factors for each analysed outcome. 
However, our study also has limitations that need to be aknowledged. First, the cross-
sectional design does not allow any causality relationships to be determined. Second, the 
study population was aged between 40 and 85 years and essentially of white European 
origin with a low prevalence of obesity. Thus, generalizability of our findings to younger, 
more obese populations of different ethnicity is not possible. Lastly, we did not use the 
dichotomized definition of REM-SDB proposed by others [2-4]. However, we believe that 
the use of REM-AHI severity categories allows more precise analysis than a dichotomous 
classification. 
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 In conclusion, our findings show that moderate-to-severe REM-SDB is highly 
prevalent in the general population, even in individuals classified as having absent or mild 
SDB, and that REM-SDB is independently associated with important cardiovascular risk 
factors such as metabolic syndrome and diabetes. Because CPAP use is often limited to 
the first part of the night (leaving the most REM-SDB untreated), our results strenghten the 
concept that patients should be encouraged to use CPAP for the whole night to obtain 
maximum benefit. 
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 Table 1. Subject's characteristics in the entire cohort based on REM-AHI severity. 
REM-AHI severity categories in the entire cohort  
  All <5/h 5-9.9/h 10-19.9/h ≥20/h p-value 
Number of subjects, % (n) 100 (2074) 22.0 (456) 16.0 (331) 21.3 (441) 40.8 (846)   
Female, % (n) 52.0 (1079) 69.7 (318)* 57.1 (189)* 49.9 (220) 41.6 (352) <0.0001 
Age, years, Median (IQR) 56.3 (48.5 - 66.2) 51.3 (45.6 - 59.6) 54.1 (47.0 - 63.1)* 55.9 (48.9 - 65.7)* 60.6 (52.5 - 68.4)*
+#
 <0.0001 
BMI, kg/m
2
, Median (IQR) 25.7 (23.2 - 28.5) 23.7 (21.5 - 26.3) 24.2 (22.1 - 26.5) 25.6 (23.3 - 27.9)*
+
 27.4 (25.0 - 30.4)*
+#
 <0.0001 
WHR, Median (IQR)   0.92 (0.87 - 0.97) 0.89 (0.84 - 0.94) 0.90 (0.85 - 0.95) 0.91 (0.87 - 0.97)*+ 0.94 (0.90 - 0.98)*+# <0.0001 
Neck circumference, Median (IQR) 37.0 (33.5 - 39.8) 34.0 (32.0 - 37.5) 35.0 (33.0 - 38.5) 37.0 (34.0 - 39.0)*
+
 38.0 (35.0 - 41.0)*
+#
 <0.0001 
Hypertension, % (n) 40.8 (846) 24.3 (111) 34.7 (115) 37.4 (165) 53.9 (455)* <0.0001 
Type 2 diabetes, % (n) 9.7 (200) 3.3 (15) 5.4 (18) 6.8 (30) 16.2 (137)* <0.0001 
Metabolic syndrome, % (n) 30.0 (623) 12.3 (56) 19.3 (64) 27.2 (120) 45.3 (383) <0.0001 
Depression, % (n) 6.2 (107) 6.3 (23) 4.6 (13) 6.6 (25) 6.6 (46) 0.668 
Antihypertensive medication, % (n) 25.7 (532) 14.5 (66) 19.9 (66) 21.5 (95) 36.1 (305)* <0.0001 
Antidepressant medication, %  (n) 5.7 (115) 7.1 (31) 3.4 (11) 4.6 (20) 6.4 (53) 0.096 
Benzodiazepines, % (n) 8.4 (171) 7.4 (33) 8.5 (28) 8.1 (35) 8.9 (75) 0.815 
Current smoking, %, (n) 18.5 (379) 20.3 (92) 18.3 (60) 17.8 (78) 17.9 (149) 0.063 
Alcohol consumption before PSG, mean (SD) 0.45 (0.89) 0.42 (0.82) 0.43 (0.82) 0.40 (0.88) 0.49 (0.93) 0.276 
Alcohol consumption weekly, mean (SD) 6.5 (7.9) 5.5 (7.2) 5.8 (6.9) 6.7 (8.2) 7.1 (8.4)* 0.007 
TST, min, Median (IQR) 406.5 (364.0 - 449.6) 409.2 (370.6 - 453.5) 411.5 (370.5 - 454.0) 415.0 (367.3 - 457.3) 397.5 (353.9 - 441.5)*
+#
 <0.0001 
TST in supine, min, Median (IQR) 120.4 (53.4 - 196.1) 105.4 (49.0 - 174.3) 125.6 (62.5 - 194.6)* 127.5 (58.4 - 187.0) 122.6 (49.6 - 209.3) 0.040 
REM time in supine, min, Median (IQR) 20.0 (2.0 - 44.2) 17.1 (0 - 42.2) 20.0 (3.1 - 47.0) 20.5 (2.1 - 40.5) 21.4 (2.9 - 46.4) 0.094 
REM time, % of TST, Median (IQR)  22.5 (18.6 - 26.1) 23.6 (19.9 - 27.0) 23.0 (19.9 - 26.3) 22.9 (19.3 - 26.2) 21.1 (17.2 - 25.4)*+# <0.0001 
SWS time, % of TST, Median (IQR)  19.4 (14.2 - 25.0) 20.8 (16.3 - 25.8) 20.0 (15.3 - 25.6) 19.8 (14.3 - 25.7) 18.0 (12.5 - 23.9)*+# <0.0001 
Arousal index, events/h, Median (IQR) 18.7 (13.8 - 25.9) 14.2 (10.4 - 19.7)* 17.1 (13.6 - 22.0)* 18.1 (14.1 - 23.8)* 23.2 (16.6 - 31.1)*
+#
 <0.0001 
Total AHI, events/h, Median (IQR)  9.8 (4.2 - 20.1) 2.0 (1.0 - 4.8) 4.3 (2.9 - 8.1)* 9.0 (6.0 - 13.5)*+ 21.4 (13.9 - 34.5)*+# <0.0001 
NREM-AHI, events/h, Median (IQR)  7.4 (2.3 - 17.2) 1.7 (0.6 - 5.0) 3.4 (1.4 - 7.8)* 6.6 (3.0 - 12.0)*+ 16.6 (8.3 - 30.1)*+# <0.0001 
REM-AHI, events/h, Median (IQR) 15.3 (5.7 - 30.3) 2.2 (0.9 - 3.4) 7.1 (6.0 - 8.6)* 14.5 (12.4 - 16.8)*
+
 34.4 (25.7 - 46.8)*
+#
 <0.0001 
REM-AHI non-supine, events/h, Median (IQR) 8.8 (2.6 – 23.0) 1.3 (0 – 2.7) 5.1 (2.2 – 7.3)* 10.4 (6.2 – 14.3)*
+
 26.7 (18.2 – 40.9)*
+#
 <0.0001 
REM-AHI supine, events/h, Median (IQR) 27.9 (8.4 - 52.7) 2.7 (0 - 6.2) 10.8 (7.0 - 23.4)* 25.1 (16.4 - 42.5)*
+
 52.2 (37.5 - 68.6)*
+#
 <0.0001 
ODI 3%, events/h, Median (IQR) 9.9 (4.3 - 19.0) 2.4 (1.0 - 5.5) 4.7 (3.0 - 9.0)* 8.7 (5.6 - 14.3)*
+
 19.8 (12.9 - 30.9)*
+#
 <0.0001 
T90, % of TST, mean (SD) 4.1 (12.3) 7.2 (1.1) 9.3 (1.4)* 13.0 (3.5)*
+
 14.3 (7.0)*
+#
 <0.0001 
ESS score, Median (IQR) 6.0 (3.0 - 9.0) 6.0 (3.0 - 8.0) 5.0 (3.0 - 9.0) 6.0 (3.8 - 8.0) 6.0 (3.0 - 9.0) 0.690 
Definition of abbreviations: AHI = apnoea–hypopnoea index; BMI = body mass index; ESS = Epworth Sleepiness Scale; IQR = interquartile range; Min = minutes; NREM = non-rapid eye movement; ODI = 
oxygen desaturation index per hour of 3% or greater; PSG = polysomnography; REM = rapid eye movement; SD = standard deviation; SWS = slow wave sleep; T90 = percentage of total sleep time with 
oxygen saturation below 90%; TST = total sleep time; WHR = waist-to-hip ratio. Alcohol consumption = mean consumption of standard drink containing 10 g of alcohol.  
Data analyzed by Pearson’s chi-square or Kruskal-Wallis followed by Mann-Whitney pairwise comparisons. *p<0.008 compared to <5/h; #p<0.008 compared to 10-19.9/h; +p<0.008 compared to 5-9.9/h. 
Number of participants with missing data: alcohol consumption before PSG (31), antidepressant medication (49), benzodiazepines (27), BMI (12), smoking (22), depression (353), diabetes (2), 
hypertension (2), neck circumference (57), REM-AHI non-supine (89), REM-AHI supine (394), REM time in supine (1), T90 (28), WHR (2). 
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 Table 2. Patient characteristics in NREM-AHI<10 subgroup based on REM-AHI severity. 
REM-AHI severity categories in NREM-AHI<10 subgroup 
  All <5/h 5-9.9/h 10-19.9/h ≥20/h p-value 
Number of subjects, % (n) 100 (1241) 33.2 (412) 22.2 (275) 23.4 (291) 21.2 (263)   
Female, % (n) 63.7 (790) 73.5 (303)* 60.7 (167) 58.8 (171) 56.7 (149) <0.0001 
Age, years, Median (IQR) 53.5 (46.7 - 63.2) 50.5 (45.3 - 58.4) 53.8 (46.5 - 62.7)* 54.4 (48.0 - 64.7)* 57.7 (49.2 - 66.7)*
+
 <0.0001 
BMI, kg/m
2
, Median (IQR) 24.7 (22.3 - 27.3) 23.4 (21.3 - 26.1) 23.9 (21.9 - 26.2) 25.4 (22.9 - 27.5)*
+
 26.4 (24.3 - 29.5)*
+#
 <0.0001 
WHR, Median (IQR)   0.90 (0.85 - 0.95) 0.89 (0.84 - 0.93) 0.89 (0.84 - 0.94) 0.90 (0.86 - 0.95)* 0.92 (0.87 - 0.96)*+ <0.0001 
Neck circumference, Median (IQR) 35.0 (33.0 - 38.0) 34.0 (32.0 - 37.0) 35.0 (33.0 - 38.0)* 36.0 (33.0 - 38.0)* 36.5 (34.5 - 39.0)*
+#
 <0.0001 
Hypertension, % (n) 32.1 (398) 22.3 (92) 32.7 (90) 33.7 (98) 45.0 (118)* <0.0001 
Type 2 diabetes, % (n) 5.4 (67) 2.2 (9) 3.6 (10) 5.5 (16) 12.2 (32)* <0.0001 
Metabolic syndrome, % (n) 20.7 (257) 10.7 (44) 17.1 (47) 22.0 (64) 38.8 (102)* <0.0001 
Depression, % (n) 7.0 (72) 6.6 (22) 5.4 (13) 7.3 (18) 8.8 (19) 0.547 
Antihypertensive medication, % (n) 18.7 (232) 11.9 (49) 18.5 (51) 18.6 (54) 29.7 (78) <0.0001 
Antidepressant medication, %  (n) 4.7 (57) 6.8 (27) 3.7 (10) 4.2 (12) 3.1 (8) 0.100 
Benzodiazepines, % (n) 7.5 (92) 6.2 (25) 9.2 (25) 5.9 (17) 9.6 (25) 0.192 
Current smoking, %, (n) 20.0 (246) 20.3 (83) 19.5 (53) 19.7 (57) 20.3 (53) 0.832 
Alcohol consumption before PSG, mean (SD) 0.41 (0.84) 0.40 (0.79) 0.45 (0.90) 0.34 (0.76) 0.47 (0.93) 0.422 
Alcohol consumption weekly, mean (SD) 5.7 (7.3) 5.3 (7.1) 5.8 (7.1) 6.1 (7.2) 5.9 (7.8) 0.380 
TST, min, Median (IQR) 409.5 (367.0 - 453.5) 411.3 (372.0 - 455.1) 411.9 (366.5 - 456.5) 419.0 (374.5 - 458.3) 394.5 (351.5 - 438.5)*
+#
 0.001 
TST in supine, min, Median (IQR) 122.3 (55.6 - 192.0) 110.0 (53.0 - 183.6) 133.0 (62.5 - 198.5) 128.9 (56.9 - 185.5) 128.8 (47.1 - 212.4) 0.148 
REM time in supine, min, Median (IQR) 94.5 (76.3 - 114.0) 21.2 (0.5 - 46.5) 23.6 (6.0 - 51.5) 25.0 (7.0 - 46.5) 28.5 (7.5 - 52.0)* 0.028 
REM time, % of TST, Median (IQR)  23.4 (19.7 - 26.8) 23.8 (20.3 - 27.2) 23.5 (20.2 - 26.3) 23.3 (19.4 - 26.8) 22.3 (17.8 - 26.2)* 0.018 
SWS time, % of TST, Median (IQR)  20.8 (16.1 - 26.0) 21.0 (16.7 - 26.0) 20.3 (15.6 - 25.9) 20.9 (15.7 - 25.9) 20.9 (16.0 - 26.1) 0.686 
Arousal index, Median (IQR) 15.3 (11.8 - 20.5) 13.8 (10.1 - 18.5) 16.5 (12.8 - 21.4)* 15.7 (12.9 - 20.5)* 16.5 (12.5 - 22.6)* <0.0001 
Total AHI, events/h, Median (IQR)  5.3 (2.4 - 8.7) 1.8 (0.9 - 3.4) 3.7 (2.8 - 6.0)* 6.6 (5.2 - 9.0)*+ 11.1 (8.9 - 13.5)*+# <0.0001 
NREM-AHI, events/h, Median (IQR)  3.1 (1.3 - 6.1) 1.4 (0.5 - 3.5) 2.6 (1.2 - 5.2)* 4.2 (2.0 - 6.5)*+ 5.6 (3.5 - 7.7)*+# <0.0001 
REM-AHI, events/h, Median (IQR) 8.6 (3.4 - 17.8) 2.1 (0.9 - 3.4) 7.1 (6.0 - 8.5)* 14.2 (12.2 - 16.5)*
+
 28.2 (13.5 - 30.2)*
+#
 <0.0001 
REM-AHI non-supine, events/h, Median (IQR) 4.7 (1.3 – 12.5) 1.2 (0 – 2.6) 5.0 (2.2 – 7.2)* 10.0 (5.6 – 14.0)*
+
 22.2 (23.5 - 35.3)*
+#
 <0.0001 
REM-AHI supine, events/h, Median (IQR) 15.0 (4.3 - 33.3) 2.7 (0 - 5.9) 10.6 (6.9 - 20.5)* 23.0 (15.9 - 37.4)*
+
 41.2 (31.3 - 53.6)*
+#
 <0.0001 
ODI 3%, events/h, Median (IQR) 5.3 (2.6 - 9.0) 2.0 (1.0 - 4.2) 4.2 (2.7 - 6.2)* 6.6 (4.7 - 8.9)*
+
 11.0 (8.8 - 14.2)*
+#
 <0.0001 
T90, % of TST, mean (SD) 2.5 (11.1) 1.1 (7.6) 1.5 (10.1) 2.9 (13.7)*
+
 5.2 (13.0)*
+#
 <0.0001 
ESS score, Median (IQR) 6.0 (3.0 - 9.0) 6.0 (3.0 - 8.0) 5.0 (3.0 - 9.0) 6.0 (3.3 - 8.0) 6.0 (4.0 - 9.0) 0.344 
Definition of abbreviations: AHI = apnoea–hypopnoea index; BMI = body mass index; ESS = Epworth Sleepiness Scale; IQR = interquartile range; Min = minutes; NREM = non-rapid eye movement; ODI = 
oxygen desaturation index per hour of 3% or greater; PSG = polysomnography; REM = rapid eye movement; SD = standard deviation; SWS = slow wave sleep; T90 = percentage of total sleep time with 
oxygen saturation below 90%; TST = total sleep time; WHR = waist-to-hip ratio. Alcohol consumption = mean consumption of standard drink containing 10 g of alcohol.  
Data analyzed by Pearson’s chi-square or Kruskal-Wallis followed by Mann-Whitney pairwise comparisons. *p<0.008 compared to <5/h; #p<0.008 compared to 10-19.9/h; +p<0.008 compared to 5-9.9/h.  
Number of participants with missing data: alcohol consumption before PSG (20), antidepressant medication (28), benzodiazepines (16), BMI (3), smoking (9), depression (206), hypertension (1), neck 
circumference (35), REM-AHI non-supine (44), REM-AHI supine (213), T90 (14), WHR (1). 
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 Table 3. Patient characteristics in AHI<10 subgroup based on REM-AHI severity. 
REM-AHI severity categories in AHI<10 subgroup 
  All <5/h 5-9.9/h 10-19.9/h ≥20/h p-value 
Number of subjects, % (n) 100 (1047) 40 (419) 26.3 (275) 24.6 (258) 9.1 (95)   
Female, % (n) 65.2 (683) 72.8 (305)* 61.5 (169) 59.3 (153) 58.9 (56) <0.0001 
Age, years, Median (IQR) 52.8 (46.2 - 62.4) 50.5 (45.4 - 58.5) 53.8 (46.5 - 63.0)* 54.4 (48.0 - 64.3)* 55.0 (47.2 - 66.1)* <0.0001 
BMI, kg/m
2
, Median (IQR) 24.3 (21.9 - 26.8) 23.4 (21.3 - 26.1) 24.0 (21.9 - 26.3) 25.3 (22.7 - 27.3)*
+
 26.3 (23.6 - 30.4)*
+#
 <0.0001 
WHR, Median (IQR)   0.90 (0.85 - 0.94) 0.89 (0.84 - 0.94) 0.89 (0.84 - 0.94) 0.90 (0.86 - 0.95)* 0.92 (0.87 - 0.97)*+ <0.0001 
Neck circumference, Median (IQR) 35.0 (33.0 - 38.0) 34.0 (32.0 - 37.0)* 35.0 (33.0 - 38.0)* 35.5 (33.0 - 38.0)* 36.0 (34.4 - 39.0)*
+
 <0.0001 
Hypertension, % (n) 29.8 (312) 22.9 (96) 32.4 (89) 33.7 (87) 42.1 (40)* <0.0001 
Type 2 diabetes, % (n) 4.3 (45) 2.4 (10) 3.6 (10) 5.4 (14) 11.6 (11)* 0.001 
Metabolic syndrome, % (n) 17.9 (187) 11.5 (48) 17.1 (47) 21.3 (55) 17.9 (187)* <0.0001 
Depression, % (n) 6.4 (56) 6.5 (22) 5.4 (13) 7.2 (16) 6.3 (5) 0.887 
Antihypertensive medication, % (n) 16.9 (177) 12.2 (51) 18.2 (50) 19.0 (49) 28.4 (27)* 0.001 
Antidepressant medication, %  (n) 4.9 (50) 6.9 (28) 3.7 (10) 4.3 (11) 1.1 (1) 0.058 
Benzodiazepines, % (n) 7.7 (79) 6.1 (25) 9.2 (25) 6.3 (16) 13.8 (13)* 0.045 
Current smoking, %, (n) 20.9 (217) 20.7 (86) 19.5 (53)* 21.8 (56)* 23.2 (22)*
+
 0.858 
Alcohol consumption before PSG, mean (SD) 0.40 (0.81) 0.39 (0.78) 0.45 (0.90) 0.35 (0.79) 0.41 (0.78) 0.511 
Alcohol consumption weekly, mean (SD) 5.7 (7.2) 5.4 (7.3) 5.8 (7.1) 6.0 (7.3) 5.6 (6.7) 0.497 
TST, min, Median (IQR) 411.0 (368.5 - 454.0) 410.5 (372.0 - 455.5) 411.5 (366.5 - 458.0) 418.8 (371.9 - 353.0) 391.5 (353.0 - 420.4)*
+#
 0.002 
TST in supine, min, Median (IQR) 121.2 (55.4 - 190.0) 109.9 (49.3 - 177.5) 133.0 (62.5 - 200.0) 127.9 (54.3 - 187.0) 131.2 (47.0 - 189.1) 0.111 
REM time in supine, min, Median (IQR) 23.2 (3.1 - 48.0) 20.6 (0.2 - 46.0) 23.6 (6.0 - 51.1) 25.0 (7.3 - 46.4) 27.8 (6.0 - 57.5) 0.062 
REM time, % of TST, Median (IQR)  23.3 (19.7 - 26.6) 23.8 (20.3 - 27.2) 23.5 (20.2 - 26.3) 23.2 (19.4 - 26.6) 20.4 (17.0 - 23.6)*+# <0.0001 
SWS time, % of TST, Median (IQR)  20.8 (16.3 - 25.9) 20.9 (16.6 - 25.9) 20.1 (15.6 - 25.9) 20.6 (15.6 - 25.9) 22.3 (18.0 - 26.1) 0.237 
Arousal index, Median (IQR) 15.2 (11.5 - 20.0) 13.8 (10.2 - 18.6) 16.5 (12.8 - 21.4)* 15.5 (12.8 - 20.1)* 15.7 (12.0 - 21.6)* <0.0001 
Total AHI, events/h, Median (IQR)  4.2 (2.1 - 6.9) 1.8 (0.9 - 3.5) 3.7 (2.8 - 6.0)* 6.3 (5.1 - 8.3)*+ 8.1 (6.9 - 9.2)*+# <0.0001 
NREM-AHI, events/h, Median (IQR)  2.4 (1.1 - 4.9) 1.5 (0.5 - 3.6) 2.6 (1.2 - 5.2)* 3.7 (1.9 - 5.7)*+ 3.2 (2.0 - 4.2)* <0.0001 
REM-AHI, events/h, Median (IQR) 6.5 (2.7 - 12.7) 2.1 (0.9 - 3.4) 7.0 (6.0 - 8.5)* 13.9 (12.0 - 16.4)*
+
 24.7 (21.7 - 28.3)*
+#
 <0.0001 
REM-AHI non-supine, events/h, Median (IQR) 3.5 (1.0 – 8.6) 1.2 (0 – 2.6) 5.0 (2.2 – 7.2)* 10.0  (5.5 – 13.6)*
+
 20.5 (7.0 – 26.4)*
+#
 <0.0001 
REM-AHI supine, events/h, Median (IQR) 10.6 (3.0 - 24.1) 2.7 (0 - 5.9) 10.6 (7.0 - 20.5)* 22.3 (15.2 - 35.1)*
+
 31.8 (25.8 - 46.0)*
+#
 <0.0001 
ODI 3%, events/h, Median (IQR) 4.4 (2.2 - 7.0) 2.0 (1.0 - 4.4) 4.2 (2.7 - 6.2) 6.2 (4.5 - 8.2)*
+
 8.4 (6.9 - 10.2)*
+#
 <0.0001 
T90, % of TST, mean (SD) 2.1 (11.1) 1.1 (7.5) 1.5 (10.1) 2.9 (14.3)*
+
 5.6 (15.7)*
+#
 <0.0001 
ESS score, Median (IQR) 6.0 (3.0 - 9.0) 6.0 (3.0 - 8.0) 5.0 (3.0 - 9.0) 5.0 (3.5 - 8.5) 6.0 (3.0 - 9.0) 0.906 
Definition of abbreviations: AHI = apnoea–hypopnoea index; BMI = body mass index; ESS = Epworth Sleepiness Scale; IQR = interquartile range; Min = minutes; NREM = non-rapid eye movement; ODI = 
oxygen desaturation index per hour of 3% or greater; PSG = polysomnography; REM = rapid eye movement; SD = standard deviation; SWS = slow wave sleep; T90 = percentage of total sleep time with 
oxygen saturation below 90%; TST = total sleep time; WHR = waist-to-hip ratio. Alcohol consumption = mean consumption of standard drink containing 10 g of alcohol.  
Data analyzed by Pearson’s chi-square or Kruskal-Wallis followed by Mann-Whitney pairwise comparisons. *p<0.008 compared to <5/h; #p<0.008 compared to 10-19.9/h; +p<0.008 compared to 5-9.9/h.  
Number of participants with missing data: alcohol consumption before PSG (19), antidepressant medication (27), benzodiazepines (15), BMI (3), smoking (7), depression (169), neck circumference (33), 
NREM-AHI supine (58), REM-AHI supine (194), T90 (12), WHR (1).
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Table 4. Associations between REM-AHI and blood pressure. 
 
 
  
Entire cohort 
NREM-AHI<10 
subgroup 
AHI<10 
subgroup 
β p-value β p-value β p-value 
Systolic blood pressure             
REM-AHI (continuous) 0.03 0.167 0.01 0.842 -0.03 0.671 
5-9.9/h 2.02 0.070 1.28 0.275 1.43 0.213 
10-19.9/h 2.11 0.051 1.80 0.135 1.61 0.181 
≥20/h 2.40 0.030 0.50 0.701 -1.18 0.486 
Diastolic blood pressure             
REM-AHI (continuous) 0.02 0.208 0.01 0.821 -0.02 0.636 
5-9.9/h 1.27 0.089 1.01 0.193 1.02 0.179 
10-19.9/h 1.20 0.097 1.12 0.159 0.90 0.255 
≥20/h 1.72 0.020 0.23 0.787 -1.19 0.289 
Definition of abbreviations: AHI = apnoea–hypopnoea index; β = linear regression coefficient beta; NREM = non-rapid 
eye movement; REM = rapid eye movement. 
Data analyzed by linear regression using REM-AHI as continuous or dummy variable with adjustment for age, sex, body 
mass index, waist-to-hip ratio, total sleep time, smoking, alcohol consumption (weekly), antihypertensive drug and log-
NREM-AHI. 
Number of participants with missing data in the models (entire cohort, NREM-AHI<10, AHI<10): systolic blood pressure 
and diastolic blood pressure (16, 6, 5). 
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Figure captions 
Figure 1. Odds ratios and 95% confidence intervals (CI) for rapid eye movement (REM) 
apnoea-hypopnoea index (AHI) severity categories in the entire cohort (n=2074 
polysomnographies). Circles represent the odds ratio and bars the 95% CI. Logistic 
regression models fitted to examine the associations for the entire cohort with metabolic 
syndrome, diabetes, hypertension and depression. Increasing REM-AHI severity was 
significantly associated with metabolic syndrome. Hypertension, diabetes and depression 
were not significantly associated with REM-sleep-disordered breathing (REM-SDB). 
Cardiovascular and metabolic comorbidities were adjusted for age, sex, body mass index, 
waist-to-hip ratio, total sleep time, smoking, alcohol consumption (weekly) and the logarithme 
of non-REM-AHI (log-NREM-AHI). Depression was adjusted for age, gender, and 
consumption of benzodiazepines, antidepressants, and log-NREM-AHI. Number of 
participants with missing data in the models: metabolic syndrome (35), diabetes (37), 
hypertension (37), depression (389).  
 
Figure 2. Odds ratios and 95% confidence intervals (CI) for rapid eye movement (REM) 
apnoea-hypopnoea index (AHI) severity categories in the subgroup with non-REM-
AHI<10/h (n=1241 polysomnographies). Circles represent the odds ratio and bars the 95% 
CI. Logistic regression models fitted to examine the associations for the entire cohort with 
metabolic syndrome, diabetes, hypertension and depression. Increasing REM-AHI severity 
was significantly associated with metabolic syndrome and diabetes. Hypertension and 
depression showed no association with REM-sleep-disordered breathing (REM-SDB). 
Cardiovascular and metabolic comorbidities were adjusted for age, sex, body mass index, 
waist-to-hip ratio, total sleep time, smoking, alcohol consumption (weekly) and the logarithme 
of non-REM-AHI (log-NREM-AHI). Depression was adjusted for age, gender, and 
consumption of benzodiazepines, antidepressants, and log-NREM-AHI. Number of 
participants with missing data in the models: metabolic syndrome (13), diabetes (13), 
hypertension (14), depression (226). 
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Figure 3. Odds ratios and 95% confidence intervals (CI) for rapid eye movement (REM) 
apnoea-hypopnoea index (AHI) severity categories in the subgroup with total AHI<10/h 
(n=1047 polysomnographies). Circles represent the odds ratio and bars the 95% CI. 
Logistic regression models fitted to examine the associations for the entire cohort with 
metabolic syndrome, diabetes, hypertension and depression. Moderate-to-severe REM 
sleep-disordered breathing (REM-SDB) was significantly associated with metabolic 
syndrome and diabetes. Diabetes, hypertension and depression showed no association with 
REM-SDB. Cardiovascular and metabolic comorbidities were adjusted for age, sex, body 
mass index, waist-to-hip ratio, total sleep time, smoking, alcohol consumption (weekly) and 
the logarithme of non-REM-AHI (log-NREM-AHI). Depression was adjusted for age, gender, 
and consumption of benzodiazepines, antidepressants, and log-NREM-AHI. Number of 
participants with missing data in the models: metabolic syndrome (11), diabetes (11), 
hypertension (11), depression (189). 
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Supplementary Table S1. Impact of a 10 events per hour increase in REM-AHI on the prevalence of comorbidities. 
 
 
  
Metabolic Syndrome Diabetes Hypertension Depression 
OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value OR (95% CI) p-value 
REM-AHI, events/h                 
Entire cohort 1.10 (1.02 - 1.18) 0.012 1.08 (1.00 - 1.18) 0.127 1.04 (1.00 - 1.11) 0.258 1.10 (1.00 - 1.25) 0.160 
NREM-AHI<10 subgroup 1.26 (1.12 - 1.40) <0.0001 1.26 (1.07 - 1.46) 0.007 1.08 (1.00 - 1.21) 0.195 1.18 (1.00 - 1.40) 0.117 
AHI<10 subgroup 1.31 (1.08 - 1.55) 0.009 1.41 (1.05 - 1.79) 0.024 1.10 (0.99 - 1.30) 0.317 1.20 (0.98 - 1.60) 0.302 
Definition of abbreviations: AHI = apnoea–hypopnoea index; CI = confidence interval; OR = Odds ratio; REM = rapid eye movement. 
Data analyzed by multivariable-adjusted logistic regression. Cardiovascular and metabolic comorbidities were adjusted for age, sex, body mass index, waist-to-hip ratio, total sleep 
time, smoking, alcohol consumption (weekly) and non-REM AHI (NREM-AHI). Depression was adjusted for age, gender, consumption of benzodiazepines and antidepressants and 
log-NREM-AHI. 
Number of participants with missing data in the models (entire cohort, NREM-AHI<10, AHI<10): systolic blood pressure and diastolic blood pressure (16, 6, 5). 
Number of participants with missing data in the models of the entire cohort (REM-AHI, REM-AHI in supine, REM-AHI non-supine): metabolic syndrome (entire cohort: 35, 424, 35; 
NREM-AHI<10 subgroup: 13, 223, 13; AHI<10 subgroup: 11, 203, 11); diabetes (entire cohort: 37, 426, 37; NREM-AHI<10 subgroup: 13, 223, 13; AHI<10 subgroup: 11, 203, 11); 
hypertension (entire cohort: 37, 426, 37; NREM-AHI<10 subgroup: 14, 224, 14; AHI<10 subgroup: 11, 203, 11); depression (entire cohort: 389, 720, 389; NREM-AHI<10 subgroup: 
226, 410, 226; AHI<10 subgroup: 189, 358, 189). 
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Supplementary Table S2. Associations between REM-AHI and blood pressure in participants free of 
antihypertensive drug use. 
 
 
  
Entire cohort 
n=1531 
NREM-AHI<10 subgroup 
n=1004 
AHI<10 subgroup 
n=866 
β p-value β p-value β p-value 
Systolic blood pressure 0.02 0.285 0.00 0.864 0.01 0.772 
REM-AHI (continuous) 0.01 0.785 -0.01 0.886 0.04 0.499 
5-9.9/h 1.27 0.274 1.03 0.393 0.96 0.422 
10-19.9/h 0.81 0.469 1.90 0.125 2.02 0.108 
≥20/h 0.47 0.680 0.33 0.815 0.18 0.925 
Diastolic blood pressure             
REM-AHI (continuous) 0.02 0.285 0.00 0.864 0.01 0.772 
5-9.9/h 0.92 0.229 1.02 0.202 0.96 0.225 
10-19.9/h 0.56 0.446 1.04 0.202 1.06 0.196 
≥20/h 1.00 0.183 0.29 0.754 -0.35 0.779 
Definition of abbreviations: AHI = apnoea–hypopnoea index; β = linear regression coefficient beta; NREM = non-rapid eye 
movement; REM = rapid eye movement. 
Data analyzed by linear regression using REM-AHI as continuous or dummy variable with adjustment for age, sex, body mass 
index, waist-to-hip ratio, total sleep time, smoking, alcohol consumption (weekly), and log-NREM-AHI. 
Number of participants with missing data in the models (entire cohort, NREM-AHI<10, AHI<10): systolic blood pressure and 
diastolic blood pressure (11, 5, 4). 
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